Clinical Trials Logo

Respiratory Tract Neoplasms clinical trials

View clinical trials related to Respiratory Tract Neoplasms.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT06177925 Recruiting - Neoplasms Clinical Trials

A Phase Ⅱ Clinical Study of Adebrelimab Combined With Chemotherapy and Concurrent Radiotherapy for Extensive-Stage Oligometastatic SCLC

Start date: December 10, 2023
Phase: Phase 2
Study type: Interventional

This is an open-label, single arm Phase II study designed to evaluate the efficacy and safety of adebelizumab combined with carboplatin/Cisplatin plus (+) etoposide and concurrent radiotherapy in the first-line treatment of patients with extensive stage oligometastatic small cell lung cancer.

NCT ID: NCT06004440 Recruiting - Lung Cancer Clinical Trials

Real World Registry for Use of the Ion Endoluminal System

Start date: September 21, 2023
Phase:
Study type: Observational [Patient Registry]

The primary objective of this study is to evaluate the performance of the Ion Endoluminal System with real-world use for pulmonary lesion localization or biopsy.

NCT ID: NCT04776447 Recruiting - Clinical trials for Carcinoma, Non-Small-Cell Lung

Atezolizumab Plus Induction Chemotherapy Plus CT-radiotherapy. (APOLO)

APOLO
Start date: June 16, 2021
Phase: Phase 2
Study type: Interventional

Open-label, non-randomized, phase II multi-centre controlled clinical trial. 51 non-resectable stage IIIA-IIIB non-small cell lung cancer patients will be enrolled in this trial to evaluate the efficacy of the treatment (Atezolizumab + Induction chemotherapy (CT) + CT-Radiotherapy) in terms of the Progression Free Survival at 12 months

NCT ID: NCT03402048 Recruiting - Neoplasms Clinical Trials

The EPIC Trial The Elderly Patient Individualized Chemotherapy Trial

EPIC
Start date: July 2012
Phase: Phase 3
Study type: Interventional

This is a randomized phase III trial that will randomize elderly patients(70 years of age and older) who are not considered eligible for standard doublet or triplet regimens. In a 2:1 fashion, patients will be randomized to the customization arm or the standard arm, respectively. This trial will be offered to patients who are previously untreated for stage IV NSCLC. The primary objective is to evaluate if chemotherapy selection based on histology and tumoral molecular determinants ERCC1, RRM1 and TS (arm A, the experimental arm) results in superior outcome in elderly patients with untreated, advanced NSCLC compared to standard of care treatments (arm B, the standard arm).